Journal to Publish Clinical Trial Protocols

Following an independent group’s finding of misreported outcomes, the Annals of Internal Medicine now requires that authors include clinical trial protocols when submitting their results.

Written byTanya Lewis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, LUXOMEDIAThe Annals of Internal Medicine is now requiring the authors of clinical trials to publish the original protocols along with the studies, as well as any changes to those protocols, Retraction Watch reported last week (May 13). The move follows an allegation by the Compare Trials project—which tracks switched outcomes in clinical trials—that five trials published in Annals over a six-week period misreported the outcomes originally specified.

“This change was something we planned prior to Compare and were intending to implement with an update of our online journal that is in process,” Darren Taichman, the executive deputy editor of Annals, told Retraction Watch. “However, the barrier Compare encountered in obtaining a protocol for one of the studies in their audit prompted us to implement it earlier.”

According to its website, the journal now requires that “authors of manuscripts that report clinical trial results must submit the original preenrollment protocol . . . with any amendments that were made. All such material must be appropriately dated. For accepted articles reporting clinical trials, Annals will publish the protocol as a supplement to the article.”

Members of Compare Trials examined Annals clinical trial reports and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies